Val Nassiri

US Director - Medical Affairs Field Based Team (Oncology) at Advanced Accelerator Applications

Val Nassiri's Professional Contact Details

Email (Verified)

****@adacap.com

Get Email Address

(212) 235-2395

Location

Othery, England, United Kingdom

Company

Advanced Accelerator Applications

Person Seniority

director

Location Postal Code

TA7

Val Nassiri's Current Company Details

Advanced Accelerator Applications

Saint-Genis-Pouilly, Rhone-Alpes, France • 277 Employees

pharmaceuticals

Advanced Accelerator Applications, S.A., a Novartis company, is an innovative radiopharmaceutical company developing, producing and commercializing molecular nuclear medicine theragnostics. AAA's theragnostic platform is based on radiolabeling a targeting molecule with either gallium Ga 68 for diagnostic use, or lutetium Lu 177 for therapy. AAA's first theragnostic pairing for neuroendocrine tumors includes diagnostic drugs NETSPOTÂ® in the US and SomaKit TOCÂ® in Europe; and therapeutic LutatheraÂ® (USAN: lutetium Lu 177 dotatate/INN: lutetium (177Lu) oxodotreotide). Additional theragnostics in development target gastrointestinal stromal tumors (GIST), and prostate and breast cancer. AAA is also an established leader in molecular nuclear diagnostic radiopharmaceuticals for PET and SPECT, mainly used in clinical oncology, cardiology and neurology. Headquartered in Saint-Genis-Pouilly, France, AAA currently has 20 production and R&D facilities, and more than 600 employees in 13 countries (France, Italy, the UK, Germany, Switzerland, Spain, Poland, Portugal, The Netherlands, Belgium, Israel, the US and Canada).

Founded Year

2002

Organization Website

adacap.com

Organization Revenue

96500

Current Technologies

youtube

css: max-width

css: @media

nginx

wordpress org